探索哮喘小气道功能障碍的相关性与程度(ATLANTIS):前瞻性队列研究基线数据
ATLANTIS研究在9国29中心纳入773例哮喘患者和99例对照,用肺功能、脉冲振荡、多次呼吸氮冲洗和CT评估小气道功能障碍(SAD)。结构方程模型显示所有生理指标均贡献于临床SAD模型,脉冲振荡和肺功能贡献最大;临床SAD分组与哮喘严重度、控制、生活质量和急性发作相关,但临床SAD与CT SAD无相关性。
要点
- SAD存在于所有严重度哮喘,重度更常见。
- 脉冲振荡和肺功能是临床SAD评分主要贡献者。
- 临床SAD分组与GINA严重度、控制、生活质量及急性发作相关。
核心结论
- SAD是哮喘复杂而沉默的特征,可由肺功能、体描、脉冲振荡和多次呼吸氮冲洗组合捕捉。
- SAD存在于所有严重度哮喘,尤其重度哮喘更常见。
- 用脉冲振荡和肺功能将临床SAD分为轻、重两组有意义,与GINA严重度、控制、生活质量和急性发作相关。
研究设计与样本
- 多国前瞻性队列研究基线评估,29中心9国,纳入773例哮喘和99例对照,年龄18-65岁。
- 哮喘诊断需客观证据支持,且稳定治疗≥8周、吸烟≤10包年。
- 评估肺功能、体描、脉冲振荡、多次呼吸氮冲洗、部分CT及问卷,用结构方程模型定义临床SAD和CT SAD评分,模型聚类分组。
主要发现
- 所有生理指标均贡献于临床SAD模型,脉冲振荡和肺功能贡献最大且两组间有差异。
- 临床SAD组1(n=452)SAD较轻,Sacin与对照相当;组2(n=312)生理指标异常更重,哮喘更严重。
- 临床SAD评分组2高于组1,且与哮喘控制、严重度和急性发作相关。
- 临床SAD与CT SAD评分无相关性。
关键数值与推荐
- 哮喘严重度按GINA 1-5级定义。
- 支气管舒张试验阳性:吸入400 μg沙丁胺醇后30分钟内FEV1变化≥12%且≥200 mL。
- 气道高反应性、PEF变异率>20%(7天)或维持治疗4周后可逆性作为诊断客观证据。
临床怎么用
- 临床可结合脉冲振荡和肺功能评估SAD,辅助识别哮喘控制差、急性发作风险高的患者。
- SAD评分可用于哮喘严重度和控制评估的补充,尤其重度哮喘。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Small airways dysfunction (SAD) is well recognised in asthma, yet its role in the severity and control of asthma is unclear. This study aimed to assess which combination of biomarkers, physiological tests, and imaging markers best measure the presence and extent of SAD in patients with asthma. METHODS: In this baseline assessment of a multinational prospective cohort study (the Assessment of Small Airways Involvement in Asthma [ATLANTIS] study), we recruited participants with and without asthma (defined as Global Initiative for Asthma severity stages 1-5) from general practices, the databases of chest physicians, and advertisements at 29 centres across nine countries (Brazil, China, Germany, Italy, Spain, the Netherlands, the UK, the USA, and Canada). All participants were aged 18-65 years, and participants with asthma had received a clinical diagnosis of asthma more than 6 months ago that had been confirmed by a chest physician. This diagnosis required support by objective evidence at baseline or during the past 5 years, which could be: positive airway hyperresponsiveness to methacholine, positive reversibility (a change in FEV1 ≥12% and ≥200 mL within 30 min) after treatment with 400 μg of salbutamol in a metered-dose inhaler with or without a spacer, variability in peak expiratory flow of more than 20% (measured over 7 days), or documented reversibility after a cycle (eg, 4 weeks) of maintenance anti-asthma treatment. The inclusion criteria also required that patients had stable asthma on any previous regular asthma treatment (including so-called rescue β2-agonists alone) at a stable dose for more than 8 weeks before baseline and had smoked for a maximum of 10 pack-years in their lifetime. Control group participants were recruited by advertisements; these participants were aged 18-65 years, had no respiratory symptoms compatible with asthma or chronic obstructive pulmonary disease, normal spirometry, and normal airways responsiveness, and had smoked for a maximum of 10 pack-years. We assessed all participants with spirometry, body plethysmography, impulse oscillometry, multiple breath nitrogen washout, CT (in selected participants), and questionnaires about asthma control, asthma-related quality of life (both in participants with asthma only), and health status. We applied structural equation modelling in participants with asthma to assess the contribution of all physiological and CT variables to SAD, from which we defined clinical SAD and CT SAD scores. We then classified patients with asthma into SAD groups with model-based clustering, and we compared asthma severity, control, and health-care use during the past year by SAD score and by SAD group. This trial is registered with ClinicalTrials.gov, number NCT02123667. FINDINGS: Between June 30, 2014, and March 3, 2017, we recruited and evaluated 773 participants with asthma and 99 control participants. All physiological measures contributed to the clinical SAD model with the structural equation modelling analysis. The prevalence of SAD in asthma was dependent on the measure used; we found the lowest prevalence of SAD associated with acinar airway ventilation heterogeneity (Sacin), an outcome determined by multiple breath nitrogen washout that reflects ventilation heterogeneity in the most peripheral, pre-acinar or acinar airways. Impulse oscillometry and spirometry results, which were used to assess dysfunction of small-sized to mid-sized airways, contributed most to the clinical SAD score and differed between the two SAD groups. Participants in clinical SAD group 1 (n=452) had milder SAD than group 2 and comparable multiple breath nitrogen washout Sacin to control participants. Participants in clinical SAD group 2 (n=312) had abnormal physiological SAD results relative to group 1, particularly their impulse oscillometry and spirometry measurements, and group 2 participants also had more severe asthma (with regard to asthma control, treatments, exacerbations, and quality of life) than group 1. Clinical SAD scores were higher (indicating more severe SAD) in group 2 than group 1, and we found that these scores were related to asthma control, severity, and exacerbations. We found no correlation between clinical SAD and CT SAD scores. INTERPRETATION: SAD is a complex and silent signature of asthma that is likely to be directly or indirectly captured by combinations of physiological tests, such as spirometry, body plethysmography, impulse oscillometry, and multiple breath nitrogen washout. SAD is present across patients with all severities of asthma, but it is particularly prevalent in severe disease. The clinical classification of SAD into two groups (a milder and a more severe group) by use of impulse oscillometry and spirometry, which are easy to use, is meaningful given its association with GINA severity stages, asthma control, quality of life, and exacerbations. FUNDING: Chiesi Farmaceutici SpA.
引用
- Postma DS, Brightling C, Baldi S, et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med. 2019. PMID: 30876830. doi:10.1016/S2213-2600(19)30049-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。